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OBJECTIVES: Polypharmacy is very common in patients with
schizophrenia. Risperidone is a commonly used antipsychotic
that is metabolized primarily by CYP2D6 and CYP3A4 in the
liver. There is a risk of drug-drug interactions with medications
that inhibit or induce these enzymes, which may affect clinical
outcomes in schizophrenic patients. This study aims to explore
and quantify the association between exposure to inhibitors
and/or inducers of CYP3A4 and CYP2D6 and the risk of discon-
tinuation of risperidone in patients with schizophrenia.
METHODS: A nested case-control study was conducted using
administrative claims data. Patients were 16-years or older with
a diagnosis of schizophrenia and at least two successive claims
for risperidone. Cases were patients that discontinued risperi-
done. Ten controls were randomly chosen for each case, match-
ing on time on treatment. For each case-control set, exposure was
deﬁned as use of an inhibitor or inducer in the one-month, three
months and six months prior to the case time. The association
between exposure and the risk of discontinuation of risperidone
was measured using conditional logistic regression models.
RESULTS: The base cohort included 20,840 patients and 10,913
cases were identiﬁed. Exposure to inhibitors was associated with
an increased risk of discontinuation in the three- and six-month
exposure windows (OR: 1.10 (1.06–1.14) and 1.11 (1.07–1.15),
respectively). The association was stronger for exposures occur-
ring when patients were new to treatment with risperidone. For
instance, the OR for exposure to an inhibitor in the last three
months was 1.16 (1.00–1.33) during the ﬁrst month of treatment
compared with 1.09 (1.00–1.19) by six months of treatment.
CONCLUSION: Co-medication with an inhibitor of CYP2D6 or
CYP3A4 is associated with a greater risk of discontinuation of
risperidone, which may have negative implications for clinical
outcomes in schizophrenia.
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OBJECTIVES: To estimate costs and outcomes associated with
atypical antipsychotic treatment and switching patterns in
patients with schizophrenia. METHODS: We developed a
Markov model that includes ﬁve health states deﬁned by scores
on the Positive And Negative Syndrome Scale (PANSS): acute
episode, persistent negative symptoms, response state, fourth-
line therapy (clozapine), and death. Following two unsuccessful
medication switches, patients transitioned to the clozapine
health state. Utility weights for each health state were deter-
mined from a published utility assessment based on PANSS.
The model accounts for adherence and discontinuation, relapse
of symptoms, and adverse events, and uses the Framingham
risk equation to account for metabolic and cardiovascular
effects. Unit health care costs were determined from standard
US data sources. Key model outputs included inpatient and
outpatient resource use and costs, costs related to cardiovascu-
lar and metabolic complications, and relapse rates and associ-
ated costs. We compared time and cost in each health state for
two antipsychotic regimens: 1) initiating therapy with a ﬁrst-
generation atypical antipsychotic and switching as needed to a
second-generation agent, and 2) initiating therapy with a
second-generation agent and switching as needed to a ﬁrst-
generation agent. RESULTS: Initiating therapy with a second-
generation atypical antipsychotic (vs the opposite strategy)
reduced time in the acute episode state (12.2 vs. 12.8 weeks)
and increased time in the response state (22.1 vs. 19.8 weeks)
at one year. This scenario was associated with lower annual
total nondrug medical costs in the acute health state ($32,185
vs. $33,193) and lower total nondrug costs in all states
($43,061 vs. $44,280). CONCLUSION: Initiating therapy with
a second-generation atypical antipsychotic was associated with
more time without symptoms than was seen when therapy was
initiated with a ﬁrst-generation agent, and lower nondrug costs
during the ﬁrst year of treatment.
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OBJECTIVES: To identify common factors in behavior and
symptom changes and to evaluate the impact of switching from
escitalopram to generic SSRIs on these factors, using data on
elderly patients in NH treated for depression. METHODS: A
retrospective chart review was conducted by an independent
contractor of patients who received escitalopram for at least 30
days (baseline period). Follow-up period was the following con-
secutive 60 days. The no-switch (NSW) group received continu-
ous escitalopram treatment for 90 days while the switch (SW)
group was switched to generic SSRIs after 30 days due to for-
mulary policies. Data on co-morbidities, behavior problems,
symptoms, concomitant medications, and resource use was
collected. Changes from baseline were coded as ‘No change’
(0), ‘Condition resolved’ (-1), and ‘Condition at follow-up not
present at baseline’ (1). Factor analysis was used to identify
common factors for changes in 19 behavior problems and 17
symptoms. Factor-based scores were calculated for each patient
and compared between the two groups with a non-parametric
Wilcoxon two-sample rank-sum test. Items not included in
factors were also compared. No adjustment for multiple com-
parisons was performed. RESULTS: A total of 432 charts were
reviewed (NSW = 244; SW = 188). Mean time on escitalopram
was 337 days for the NSW group and 290 for the SW group;
mean age was 82 and 80 years respectively. Two behavior
problem factors characterizing disruptive behavior and mental
problems, and two symptom factors characterizing abdominal
and physical discomfort were found to be signiﬁcantly worse
for the SW group (two-sided p-value < 0.05). The SW group
also had an increase in concomitant medication use. CONCLU-
SION: This study suggests that formulary decisions to alter
drug administration for non-medical reasons in elderly NH
patients who receive stable escitalopram treatment may result
in reduced quality of care (increase in behavior problems and
symptoms), and an increase in the use of non antidepressant
medications.
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